Therapeutic agent for urological cancer which is characterized by being administered with IL-6 inhibitor and CCR2 inhibitor in combination
AssigneesTokyo Women's Medical University, Hiroshima University, Chugai Seiyaku Kabushiki Kaisha
InventorsHiroaki Honda, Kohei Kobatake
Life of this patent
Estimating the term…
Abstract
Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided.
Claims13
A method for treating bladder cancer in a bladder of an individual, the method comprising administering to the individual an anti-IL-6 receptor antibody and propagermanium,
- wherein the individual's bladder cancer has one or more of:
- lysine (K)-specific demethylase 6A (KDM6A) function deficiency, inactivation of KDM6A, and absence of KDM6A protein expression.
A method for inhibiting growth of a bladder tumor in a bladder of an individual, the method comprising administering to the individual an anti-IL-6 receptor antibody and propagermanium,
- wherein the individual's bladder tumor has one or more of:
- KDM6A function deficiency, inactivation of KDM6A, and absence of KDM6A protein expression.
Dependencies are inferred from the claim text.